Townhall··Monday, November 9, 2026, 7:30 PM
FDA Now Requiring GLP-1 Makers to Warn About Rare but Severe Eye Condition
The FDA is officially requiring pharmaceutical companies to add information about the risk of a rare but serious eye condition to their GLP-1 medications’ Warnings and Precautions section.
Read the full story at Townhall
Opens townhall.com in a new tab.
What do you think?